EYPT insider transactions
EyePoint Inc. (EYPT) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for EYPT
- SEC Form 4 filed by Ribeiro Ramiro4 - EyePoint, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Duker Jay S.4 - EyePoint, Inc. (0001314102) (Issuer)
- President and CEO Duker Jay S. bought $19,724 worth of shares (1,500 units at $13.15) (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- Chief Financial Officer Elston George gifted 5,000 shares and received a gift of 5,000 shares, decreasing direct ownership by 5% to 87,818 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- Chief Medical Officer Ribeiro Ramiro sold $43,572 worth of shares (2,438 units at $17.87) and exercised 2,438 shares at a strike of $8.26 (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- Chief Medical Officer Ribeiro Ramiro sold $36,555 worth of shares (2,437 units at $15.00) and exercised 2,437 shares at a strike of $8.26 (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- Director Lurker Nancy converted options into 75,133 shares, increasing direct ownership by 34% to 294,346 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- President and CEO Duker Jay S. converted options into 20,793 shares and covered exercise/tax liability with 10,054 shares, increasing direct ownership by 16% to 77,752 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- Chief Financial Officer Elston George converted options into 15,285 shares and covered exercise/tax liability with 4,487 shares, increasing direct ownership by 13% to 91,852 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- Chief Medical Officer Ribeiro Ramiro exercised 29,250 shares at a strike of $8.26 and sold $727,319 worth of shares (42,544 units at $17.10), closing all direct ownership in the company (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- Chief Medical Officer Ribeiro Ramiro converted options into 19,667 shares and covered exercise/tax liability with 6,373 shares (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- President and CEO Duker Jay S. converted options into 95,000 shares and covered exercise/tax liability with 37,952 shares, increasing direct ownership by 572% to 67,013 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- Chief Financial Officer Elston George converted options into 34,667 shares and covered exercise/tax liability with 10,727 shares, increasing direct ownership by 42% to 81,054 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Zaderej Karen L.4 - EyePoint, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Sanders Reginald J.4 - EyePoint, Inc. (0001314102) (Issuer)
- Director Lurker Nancy converted options into 12,666 shares, increasing direct ownership by 6% to 219,213 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Landis John B.4 - EyePoint, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Duty Stuart4 - EyePoint, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Hassan Fred4 - EyePoint, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Dicicco Wendy F4 - EyePoint, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Ando Goran4 - EyePoint, Inc. (0001314102) (Issuer)
- Chief Financial Officer Elston George gifted 5,000 shares and received a gift of 5,000 shares, decreasing direct ownership by 8% to 57,114 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- Former 10% Owner Cormorant Asset Management, Lp sold $942,240 worth of shares (60,000 units at $15.70) (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- Director Lurker Nancy sold $140,477 worth of shares (9,300 units at $15.11), decreasing direct ownership by 4% to 206,547 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by EyePoint Pharmaceuticals Inc.4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Chief Medical Officer Ribeiro Ramiro sold $31,602 worth of shares (2,722 units at $11.61), closing all direct ownership in the company (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Chief Financial Officer Elston George gifted 20,000 shares and received a gift of 20,000 shares, decreasing direct ownership by 24% to 62,114 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Director Zaderej Karen L. converted options into 2,000 shares, increasing direct ownership by 5% to 38,500 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- President and CEO Duker Jay S. converted options into 16,667 shares and covered exercise/tax liability with 7,688 shares, increasing direct ownership by 911% to 9,965 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Director Lurker Nancy converted options into 11,111 shares, increasing direct ownership by 5% to 216,547 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Lurker Nancy4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- President and CEO Duker Jay S. disposed of $465,220 worth of shares (56,665 units at $8.21), decreasing direct ownership by 98% to 986 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Chief Financial Officer Elston George converted options into 7,500 shares and covered exercise/tax liability with 2,202 shares, increasing direct ownership by 7% to 80,848 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Director Zaderej Karen L. bought $59,000 worth of shares (10,000 units at $5.90), increasing direct ownership by 38% to 36,500 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Director Zaderej Karen L. bought $54,450 worth of shares (10,000 units at $5.45), increasing direct ownership by 61% to 26,500 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- President and CEO Duker Jay S. disposed of $123,100 worth of shares (20,000 units at $6.16), decreasing direct ownership by 26% to 57,651 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- President and CEO Duker Jay S. converted options into 7,000 shares and covered exercise/tax liability with 2,055 shares, increasing direct ownership by 7% to 77,651 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Chief Financial Officer Elston George converted options into 5,834 shares, increasing direct ownership by 8% to 75,550 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Director Lurker Nancy converted options into 20,000 shares, increasing direct ownership by 11% to 205,436 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Sanders Reginald J.4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- SEC Form 3 filed by new insider Sanders Reginald J.3 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Hassan Fred4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Ando Goran4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Zaderej Karen L.4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Duty Stuart4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Dicicco Wendy F4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Director Landis John B. converted options into 10,000 shares, increasing direct ownership by 88% to 21,400 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Chief Financial Officer Elston George converted options into 30,285 shares and covered exercise/tax liability with 10,075 shares, increasing direct ownership by 42% to 68,566 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Ribeiro Ramiro4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Director Lurker Nancy converted options into 87,801 shares, increasing direct ownership by 90% to 185,436 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- President and CEO Duker Jay S. converted options into 50,794 shares and covered exercise/tax liability with 16,115 shares, increasing direct ownership by 91% to 72,706 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Hassan Fred4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- SEC Form 3 filed by new insider Hassan Fred3 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Director Dicicco Wendy F bought $19,997 worth of shares (2,567 units at $7.79), increasing direct ownership by 35% to 9,967 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Director Ando Goran bought $39,750 worth of shares (5,000 units at $7.95), increasing direct ownership by 61% to 13,150 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Director Zaderej Karen L. bought $99,750 worth of shares (12,500 units at $7.98), increasing direct ownership by 312% to 16,500 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Director Lurker Nancy bought $25,003 worth of shares (3,173 units at $7.88), increasing direct ownership by 3% to 97,635 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- SEC Form 4 filed by Director Lurker Nancy4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- Director Guyer David R exercised 9,775 shares at a strike of $3.34 and sold $116,995 worth of shares (11,625 units at $10.06), decreasing direct ownership by 50% to 1,850 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
- President and CEO Duker Jay S. covered exercise/tax liability with 8,059 shares and converted options into 16,666 shares, increasing direct ownership by 29% to 38,027 units (SEC Form 4)4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)